GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BSP:GILD34) » Definitions » Cyclically Adjusted FCF per Share

Gilead Sciences (BSP:GILD34) Cyclically Adjusted FCF per Share : R$27.34 (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Gilead Sciences's adjusted free cash flow per share for the three months ended in Jun. 2024 was R$2.572. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$27.34 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Gilead Sciences's average Cyclically Adjusted FCF Growth Rate was 3.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 11.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.90% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 20.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Gilead Sciences was 97.90% per year. The lowest was 9.40% per year. And the median was 29.80% per year.

As of today (2024-09-20), Gilead Sciences's current stock price is R$229.54. Gilead Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 was R$27.34. Gilead Sciences's Cyclically Adjusted Price-to-FCF of today is 8.40.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Gilead Sciences was 66.90. The lowest was 6.45. And the median was 10.84.


Gilead Sciences Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted FCF per Share Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.35 17.68 22.91 23.39 23.15

Gilead Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.89 24.55 23.15 24.66 27.34

Competitive Comparison of Gilead Sciences's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted Price-to-FCF falls into.



Gilead Sciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=2.572/132.5538*132.5538
=2.572

Current CPI (Jun. 2024) = 132.5538.

Gilead Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 2.791 100.428 3.684
201412 2.353 99.070 3.148
201503 5.583 99.621 7.429
201506 5.543 100.684 7.298
201509 4.947 100.392 6.532
201512 7.430 99.792 9.869
201603 5.176 100.470 6.829
201606 6.040 101.688 7.873
201609 5.096 101.861 6.632
201612 4.265 101.863 5.550
201703 3.325 102.862 4.285
201706 4.257 103.349 5.460
201709 3.046 104.136 3.877
201712 3.164 104.011 4.032
201803 2.556 105.290 3.218
201806 1.839 106.317 2.293
201809 3.214 106.507 4.000
201812 3.149 105.998 3.938
201903 2.006 107.251 2.479
201906 3.256 108.070 3.994
201909 3.975 108.329 4.864
201912 3.829 108.420 4.681
202003 2.433 108.902 2.961
202006 5.009 108.767 6.104
202009 4.486 109.815 5.415
202012 3.484 109.897 4.202
202103 5.459 111.754 6.475
202106 4.384 114.631 5.069
202109 6.513 115.734 7.460
202112 6.831 117.630 7.698
202203 3.141 121.301 3.432
202206 3.323 125.017 3.523
202209 5.626 125.227 5.955
202212 4.947 125.222 5.237
202303 3.377 127.348 3.515
202306 4.242 128.729 4.368
202309 3.208 129.860 3.275
202312 3.814 129.419 3.906
202403 4.221 131.776 4.246
202406 2.572 132.554 2.572

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Gilead Sciences  (BSP:GILD34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Gilead Sciences's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=229.54/27.34
=8.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Gilead Sciences was 66.90. The lowest was 6.45. And the median was 10.84.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Gilead Sciences Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences Headlines

No Headlines